New cocktail of drugs takes on tough pancreatic cancer
NCT ID NCT05481476
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a combination of three drugs—surufatinib, sintilimab, and a standard chemotherapy (nab-paclitaxel plus gemcitabine)—as a first treatment for people with advanced or metastatic pancreatic cancer. The study enrolled 32 participants and aims to see how many respond to the treatment. It is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib, sintilimab, nab-paclitaxel, gemcitabine
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced pancreatic cancer, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 32 participants and no comparison group. The combination may cause significant side effects and may not prove more effective than standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer center of SunYat-sen University
Guangzhou, Guangdong, 510060, China